DarshanTalks Podcast

Send us Fan Mail

In December 2023, two US senators raised concerns, urging the government to scrutinize the FDA's oversight of medical device recalls, notably amidst the ongoing Phillips Respironics recall.

Join us today as we delve into the world of medical device recalls. Facing a recall is every manufacturer's nightmare, but handling it right is paramount. It safeguards patients, preserves reputations, and sidesteps legal nightmares.

Educate Yourself: The first step? Knowledge is power. Familiarize yourself with FDA guidance – understanding what you can, should, and must do. Develop policies consistent with this guidance to fortify your approach.

Transparency Is Key: Building trust is pivotal. Be upfront with the FDA when necessary. Clear, concise communication lays the foundation for swift and effective action.

Meticulous Planning: Plan with precision. Consider logistics and support. Identify affected devices, create a comprehensive notification strategy, and establish clear instructions for replacement or return. A well-thought-out plan is your best defense.

Legal Support Matters: Recalls happen, but with the right legal partner, you can minimize the impact. The Kulkarni Law Firm is here to help you navigate recalls with reassurance, ensuring the protection of your patients and your business.

Trust the Kulkarni Law Firm to guide you through the maze of medical device recalls, ensuring minimal scars and maximum protection. The path to a well-managed recall starts here.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In a congruency review, the primary objective is to ensure alignment across various elements in clinical research. The initial crucial step involves accurately analyzing Medicare coverage, determining designations based on National and Local Coverage Determinations. This forms the foundation for what is billed to the study sponsor and insurance. Any discrepancies at this stage can lead to downstream errors.

Following the coverage analysis, it becomes imperative to align the calendar with the protocol's schedule of events and the designated elements from the coverage analysis. Once the calendar is established, the focus shifts to the budget negotiation phase. Multiple touchpoints during budget negotiations necessitate periodic checks to confirm alignment with the calendar and coverage analysis designations.

On the contractual side, congruency revolves around matching the contract and budget provisions. This involves verifying that payment terms and the final budget in the contract align with the negotiated terms. Another critical aspect is ensuring congruency between the informed consent and the contract, specifically focusing on subject injury language. Standardized language for subject injury in both the informed consent and contract streamlines the congruency process. Deviations from these standards trigger communication between those handling the informed consent and contract to ensure alignment. This meticulous congruency review safeguards against discrepancies and ensures a seamless process in clinical research.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

We delve into the growing allure of clinical research sites and organizations for private equity firms. Backed by BPOC, these investments signify more than just single business deals; they are a testament to the increasing interest in fueling healthcare innovation and services.

As this trend gains momentum, thorough due diligence becomes crucial in navigating the complexities of these acquisitions. The Kulkarni Law Firm, specializing in Life Sciences law, plays a pivotal role in providing comprehensive support for regulatory compliance, contract reviews, and risk assessments. Daron emphasizes that these investments go beyond financial gains, contributing to the redefinition of the healthcare investment landscape.

The Kulkarni Law Firm keeps a watchful eye on the latest updates from the Department of Justice (DOJ), Office of Inspector General (OIG), and the Food and Drug Administration (FDA), ensuring that clients are well-informed and compliant. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, the focus is on navigating the complex landscape of off-label information sharing, exploring legal aspects in the context of the life sciences industry. Sponsored by the Kulkarni Law Firm, the episode highlights key points:

1. Scientific discussions: Courts are generally cautious about FDA scrutiny in scientific discussions, such as those in academic conferences or scholarly articles, falling within FDA safe harbors.

2. Consistent with label guidance from the FDA: Sharing information aligning with the appropriate use of a drug or device, even if not explicitly mentioned, is legally acceptable.

3. FDAMA 114:  The guidance emphasizes sharing health economic information, including off-label data, with specific entities.

4. SIUU guidance: It introduces a nuanced framework for discussing information implying off-label use, necessitating companies' awareness of its implications.

5. Education and non-company representatives: Engaging in discussions independent of pharmaceutical companies, provide crucial avenues for off-label information sharing, avoiding FDA scrutiny.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Darshan discussed crucial updates to the Department of Justice's (DOJ) corporate enforcement policies, particularly impacting FDA-regulated industries like pharmaceuticals and medical devices. The DOJ's focus on mergers and acquisitions (M&A) emphasizes the importance of compliance professionals throughout the entire process.

Key Highlights:
1. Corporate Enforcement Policies Update: The DOJ has introduced significant changes to its corporate enforcement policies, impacting companies engaged in M&A transactions. Compliance professionals are now essential stakeholders at the due diligence table.

2. Antitrust Division's Impact on Pharma: Recent cases involving pharmaceutical companies Teva and Glenmark showcased the DOJ's shift in approach. Divestiture of a core product was required, marking the first instance of such a demand in a corporate criminal resolution.

3. Compliance Program and Compensation: The new pilot program mandates companies to incorporate compliance-promoting criteria into their compensation systems. The DOJ urges companies to address this now, emphasizing the need for proactive compliance policies.

4. Voluntary Self-Disclosure Policy: The DOJ announced a voluntary self-disclosure policy, creating a safe harbor for companies that promptly report wrongdoing. The policy encourages self-reporting, offering a presumption of declination for qualifying companies.

5. Qualification for Safe Harbor: Companies must disclose misconduct within six months of acquisition, with one year to fully remediate. These deadlines may be extended based on case specifics. The Safe Harbor applies only to criminal conduct in bona fide M&A transactions.

6. DOJ Principles: The DOJ aims to hold wrongdoers accountable, incentivize compliance, and deter repeat offenses. The new policy offers a presumption of declination for companies self-disclosing, cooperating, and remediating.

7. Impact on Pharma and Device Companies: FDA-regulated industries, particularly pharmaceutical and device manufacturers, may benefit from the clear safe harbor. Voluntary self-disclosure, under the new policy, could become more common in the life sciences sector.

8. Considerations and Conclusion: Companies must carefully evaluate when self-disclosure is appropriate, with minor regulatory violations potentially better handled directly with the FDA. Compliance teams play a vital role, and ongoing developments at the intersection of compliance and FDA regulation will be closely monitored.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this podcast, we discuss the legal and regulatory factors for securing approval for your digital speaker program. Key points include 
prioritizing audience privacy, 
adhering to FTC disclosure regulations, 
explicit audience definition, 
distinguishing between educational and promotional content, and 
navigating health versus product claims. 

Link to the detailed podcast:  https://www.youtube.com/watch?v=MH6UEY_I-kI

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

FDA Issues Crucial Guidance on Prescription Drug Software! 

Darshan Kulkarni delves into the FDA's recent guidance on prescription drug-related software. The discussion revolves around three key considerations:
1. software functions, 
2. end-user output, and 
3. regulatory guidelines. 

Notably, the FDA emphasizes distinguishing between functions relying on direct device data transfer and those that don't. The document also outlines the significance of characterizing software output, such as symptom data and alerts. Lastly, regulatory guidelines stress that functions not directly transferring device information should be omitted from product information unless essential for safe use, with details to be determined on a case-by-case basis. Tune in for expert insights into this pivotal FDA update!

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Insider Exposes crucial missing step in Clinical Trial Agreements activation - Congruency Review Details Revealed!

In the clinical trial agreement activation pathway, the journey involves several critical steps. It begins with the signing of the Confidentiality Disclosure Agreement (CDA), followed by the study team's review of the protocol and feasibility goals. Once the study gets the green light, the congruency review phase becomes crucial. This phase kicks off with a Medicare coverage analysis to determine what falls under research billing and sponsor billing versus insurance billing.

The Medicare coverage analysis further involves creating a detailed calendar and schedule of events in the clinical trial management system. Budget negotiations come into play, and once finalized, the financial console aligns with the clinical trial management system calendar. Simultaneously, contract and informed consent negotiations occur, often involving multiple groups within the institution and various vendors.

Despite the complexity, there's a notable gap in the industry – the lack of comprehensive congruency review. This gap is observed both on the site side and the pharmaceutical side. Many times, discrepancies arise when regulatory discussions conflict with legal interpretations, and there's no final congruency review to ensure alignment between the Medicare coverage analysis, calendar, budget, contract, and informed consent form. Bridging this gap becomes pivotal to ensure a seamless and error-free process.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Accelerate your digital speaker program review with these 5 game-changing strategies:
 Policy Creation & Training
 Pre-reviews
 AI-based Reviews
  Modular Reviews
Applying Quality Learnings Across the Program

Dive deeper into each strategy on our podcast! 

Watch the full podcast- https://www.youtube.com/watch?v=Ud8jn4c3cCM 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Darshan Kulkarni emphasizes the importance of selecting the right company for clinical trial recruitment. Key considerations include the company's experience and expertise in a specific disease state or area, its reach (national, international, or local), and the associated costs. He warns against the trend of traditional marketing companies entering the clinical trial recruitment space, advising careful assessment of their experience and disease state knowledge. He also suggests that while this trend is emerging, its ultimate impact remains uncertain. Additionally, he concludes by encouraging those in need of assistance with training, policy development, or gap analyses to contact Darshan Kulkarni at [email protected]

Support the show

www.kulkarnilawfirm.com